Engineered T Cells for the Adoptive Therapy of B-Cell Chronic Lymphocytic Leukaemia
B-cell chronic lymphocytic leukaemia (B-CLL) remains an incurable disease due to the high risk of relapse, even after complete remission, raising the need to control and eliminate residual tumor cells in long term. Adoptive T cell therapy with genetically engineered specificity is thought to fulfil...
Saved in:
Main Authors: | Philipp Koehler, Patrick Schmidt, Andreas A. Hombach, Michael Hallek, Hinrich Abken |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | Advances in Hematology |
Online Access: | http://dx.doi.org/10.1155/2012/595060 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Weal and woe of interleukin-18 in the T cell therapy of cancer
by: Christoph Kessel, et al.
Published: (2025-01-01) -
Colonic Involvement in a Patient with Chronic Lymphocytic Leukaemia
by: P. E. T. Arkkila, et al.
Published: (2008-01-01) -
Consensus guidelines for the management of treatment-naïve chronic lymphocytic leukaemia in Singapore (2024)
by: Yeow Tee Goh, et al.
Published: (2025-01-01) -
Solid lipid nanoparticles for increased oral bioavailability of acalabrutinib in chronic lymphocytic leukaemia
by: Swagata Sinha, et al.
Published: (2024-12-01) -
Interleukin-6 and interleukin-6 receptor secretion by chronic lymphatic leukaemia and normal B lymphocytes: effect of PMA and PWM
by: I. Drucker, et al.
Published: (1997-01-01)